26/02/2021
This study estimates a high effectiveness of the BNT162b2 vaccine for preventing symptomatic Covid-19 in a noncontrolled setting, similar to the vaccine efficacy reported in the randomized trial.
This study also suggests that effectiveness is high for the more serious outcomes: hospitalization, severe illness, and death.
Furthermore, the estimated benefit increases in magnitude as time passes.
These results strengthen the expectation that newly approved vaccines can help to mitigate the profound global effects of the Covid-19 pandemic.
Original Article from The New England Journal of Medicine — BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting